> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CDER Tests Communications for Clarity
- URL: https://www.fdaweb.com/cder-tests-communications-for-clarity/
- Published: 2024-02-08T12:00:00.000Z
- Updated: 2026-09-14T14:22:32.000Z
- Author: David McFarland
- Tags: Drugs, FDA Policy/General, #legacy-id-D5156320

Social and behavioral scientists working in the CDER Office of Communications are testing some Center drug-related messages and information to ensure they are clear and understandable to their target audiences. **Alexandria Smith**, a social scientist on the Research and Risk Communications staff, says in an online [post](https://www.fda.gov/drugs/news-events-human-drugs/cder-communications-testing-optimizing-drug-information-through-target-audience-feedback?utm%5Fmedium=email&utm%5Fsource=govdelivery) that the testing is being conducted with both FDA volunteers and external patients, consumers, and healthcare professionals.

The communications researchers work with CDER teams that want to test specific messages to identify the people most likely to see or be interested in the communication.

Smith describes a recent project that tested a fact sheet on biosimilars and interchangeable biosimilars. Feedback obtained from test participants was used to clarify the information presented and create a fact sheet to share with the public that better explained the medicines, she says.

“The primary objective of communications testing is to help make sure that information we provide about medicines is clear and understandable, even when the topic is complex or technical,” Smith says. “We want to make sure we are providing the information people need and want to help them make decisions about their health. We also want to know if there are any problems with the information or how it was presented.”